CSL Limited (ASX: CSL)
Australia
· Delayed Price · Currency is AUD | Market Cap | 132.54B |
| Revenue (ttm) | 22.18B |
| Net Income (ttm) | 3.96B |
| Shares Out | 484.21M |
| EPS (ttm) | 8.17 |
| PE Ratio | 33.51 |
| Forward PE | 26.41 |
| Dividend | 4.07 (1.48%) |
| Ex-Dividend Date | Sep 9, 2024 |
| Volume | 993,903 |
| Open | 275.67 |
| Previous Close | 274.30 |
| Day's Range | 273.07 - 276.85 |
| 52-Week Range | 256.15 - 313.55 |
| Beta | 0.33 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 10, 2025 |
About CSL Limited
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron de... [Read more]
Financial Performance
In 2024, CSL Limited's revenue was $14.80 billion, an increase of 11.19% compared to the previous year's $13.31 billion. Earnings were $2.64 billion, an increase of 20.42%.
Financial numbers in USD Financial StatementsNews
New Data Presented at IDWeek 2024 Show Adjuvanted and High-Dose Influenza Vaccines are Comparable in Protecting Adults 65 Years of Age and Older Against Seasonal Influenza
Results of the first season of a randomized study showed adjuvanted and high-dose influenza vaccines did not differ in effectiveness against PCR-confirmed influenza. This is the first randomized study...
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Temporary marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial ST. GALLEN, Switzerland and SAN DIEGO, Oct. 17, 2024 /PRNewsw...
CSL Seqirus Presents Data at IDWeek 2024 Highlighting the Urgent Need to Increase Influenza Vaccination Rates and the Benefits of Cell-Based Influenza Vaccines
Analysis from a dynamic model showed the need to increase influenza vaccination rates in the U.S. to at least 45% to avoid saturation of hospital system resources, particularly in intensive care units...
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE: GSK), Sanofi SA (NASDAQ: SNY) and Australian firm CSL Limited (OTC: CSLLY) to more than double the U.S. supply o...
CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian Influenza
CSL Seqirus has received a Biomedical Advanced Research and Development Authority (BARDA) award to complete the fill and finish process for additional pre-pandemic vaccines to further support the U.S....
Sanofi, GSK, CSL Tapped to Expand US Bird Flu Vaccine Supply
GSK Plc, Sanofi and CSL Ltd. secured $72 million from the US government to ramp up production of bird flu vaccines as a nationwide outbreak among livestock and poultry has led to several human infecti...
CSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza Vaccinations
Results from real-world evidence (RWE) studies to be presented at OPTIONS XII show the effectiveness of cell-based and MF59® adjuvanted influenza vaccines. Results from different studies suggested imp...
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
Head-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over conventional mRNA in duration of immune response; Results highlight CSL and ...
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and self-amplifying messenger RNA (sa-mRNA) pioneer Arcturus Therapeutics (...
CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak
Biomedical Advanced Research and Development Authority (BARDA) and CSL Seqirus will expand their reserves of MF59® adjuvant to the equivalent of 40 million doses as part of the National Pre-Pandemic I...
Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
Veltassa ® offers effective and well-tolerated long-term potassium control in chronic kidney disease and chronic heart failure patients 1-5 Zeria Pharmaceutical Co., Ltd. to market Veltassa® in Japan...
Mark Cuban Foundation and CSL Bring Free AI Bootcamp to Philadelphia Teens
PHILADELPHIA, Sept. 17, 2024 (GLOBE NEWSWIRE) -- In an era where artificial intelligence (AI) is transforming industries and reshaping our daily lives, it is more important than ever to equip the next...
CSL Joins Accumulus Synergy to Drive Industry Change
Following the launch of Accumulus Synergy's innovative cloud-based information exchange platform, CSL joins the nonprofit industry association Following the launch of Accumulus Synergy's innovative cl...
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
Approval underscores CSL and Arcturus Therapeutics' commitment to delivering disruptive technologies to combat COVID-19 and other respiratory viral diseases to protect public health KOSTAIVE®, the wor...
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
KING OF PRUSSIA, PA & SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and sa-mRNA pioneer Arcturus Therapeutics today announced that Japan's...
CSL Limited: Good Results Overshadowed By Below-Expectations Guidance
CSL Limited's FY 2024 results were strong, but FY 2025 guidance fell short due to expected underperformance in certain segments. Read why CMXHF stock is a Hold.
CSL Limited (CSLLY) Q4 2024 Earnings Call Transcript
CSL Limited (OTCQX:CSLLY) Q4 2024 Results Conference Call August 12, 2024 9:00 PM ETCompany ParticipantsJoy Linton - CFOChris Cooper - Head, IRPaul McKenzie...
Australia's CSL falls on weaker-than-expected annual profit forecast
Shares of CSL Ltd fell more than 3% on Tuesday after the Australian biotech firm forecast an annual profit that was higher than a year earlier but below market consensus.
CSL Seqirus Begins Shipping Its Portfolio of Influenza Vaccines for the 2024/25 Flu Season
CSL Seqirus is the only manufacturer to offer a differentiated influenza vaccine for all eligible people aged six months and older in the United States. Centers for Disease Control and Prevention (CDC...
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) -- Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etra...
CSL Seqirus, a Proud Champion of Pandemic Preparedness, Announces U.S. Government Award in Response to Avian Influenza
CSL Seqirus to complete the fill and finish process for pre-pandemic vaccine to support the U.S. government's outbreak and preparedness response. Outbreaks of highly pathogenic avian influenza (HPAI) ...
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan. These results add to recently published data on ARCT-154 demonstrating superior immunogen...
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
KING OF PRUSSIA, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announce Nature Commun...
Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons
A real-world evidence (RWE) study recently published in Open Forum Infectious Diseases (OFID) examined three consecutive U.S. flu seasons in the United States. The study suggests that cell-based quadr...
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful r...